EMEA-000019-PIP03-08
Key facts
| Active substance |
everolimus
|
| Therapeutic area |
Oncology
|
| Decision number |
P/67/2008
|
| PIP number |
EMEA-000019-PIP03-08
|
| Pharmaceutical form(s) |
Tablet
|
| Condition(s) / indication(s) |
Carcinoid tumours
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Novartis Europharm Ltd
E-mail: paediatric.enquiries@novartis.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|